A small sample study of melanoma patients demonstrated that PD-1+ CD8+ tumor-infiltrating lymphocytes (TILs) in the fresh tumor tissues were identified as tumor-reactive immune cells and implied that PD-1+ CD8+ TILs could function as a potential predictive biomarker of anti-tumor immunotherapy [26]. The gene discussed is CD8A; the disease is melanoma.